Antibiotic Treatment Type and Treatment Length Among 431 Patients With Lyme Neuroborreliosis
| Treatment . | No. (%) of Patients . | Mean Total Length of Treatment, d (Range) . | 1995–1999 . | 2000–2004 . | 2005–2009 . | 2010–2014 . |
|---|---|---|---|---|---|---|
| Penicillin G IV | 175 (40.6) | 10 (7–21) | 42 (60.0) | 66 (55.5) | 62 (44.6) | 5 (4.9) |
| Penicillin V PO | 1 (0.2) | 10 | 1 (1.4) | |||
| Doxycycline PO | 47 (10.9) | 21 (10–31) | 1 (1.4) | 10 (8.4) | 11 (7.9) | 25 (24.3) |
| Ceftriaxone IV | 85 (19.7) | 14 (10–24) | 15 (21.4) | 15 (12.6) | 24 (17.3) | 31 (30.1) |
| Ceftriaxone IV + doxycycline PO | 39 (9.0) | 21 (14–42) | 3 (4.3) | 8 (5.8) | 28 (27.2) | |
| Penicillin G IV + ceftriaxone IV | 38 (8.8) | 15 (1–30) | 5 (7.1) | 11 (9.2) | 12 (8.6) | 10 (9.7) |
| Ceftriaxone IV + penicillin V PO | 3 (0.7) | 14 (9–21) | 1 (0.8) | 2 (1.4) | ||
| Penicillin G IV + doxycycline | 12 (2.8) | 21 (14–44) | 1 (1.4) | 3 (2.5) | 8 (5.8) | |
| Penicillin G IV + penicillin V PO | 3 (0.7) | 14 (14) | 1 (0.8) | 2 (1.4) | ||
| Penicillin G IV + ceftriaxone IV + doxycycline | 15 (3.5) | 21 (20–73) | 1 (1.4) | 9 (7.6) | 3 (2.2) | 2 (1.9) |
| No antibiotics | 13 (3.0) | … | 1 (1.4) | 3 (2.5) | 7 (5.0) | 2 (1.9) |
| Total No. of patients | 431 | … | 70 | 119 | 139 | 103 |
| Treatment . | No. (%) of Patients . | Mean Total Length of Treatment, d (Range) . | 1995–1999 . | 2000–2004 . | 2005–2009 . | 2010–2014 . |
|---|---|---|---|---|---|---|
| Penicillin G IV | 175 (40.6) | 10 (7–21) | 42 (60.0) | 66 (55.5) | 62 (44.6) | 5 (4.9) |
| Penicillin V PO | 1 (0.2) | 10 | 1 (1.4) | |||
| Doxycycline PO | 47 (10.9) | 21 (10–31) | 1 (1.4) | 10 (8.4) | 11 (7.9) | 25 (24.3) |
| Ceftriaxone IV | 85 (19.7) | 14 (10–24) | 15 (21.4) | 15 (12.6) | 24 (17.3) | 31 (30.1) |
| Ceftriaxone IV + doxycycline PO | 39 (9.0) | 21 (14–42) | 3 (4.3) | 8 (5.8) | 28 (27.2) | |
| Penicillin G IV + ceftriaxone IV | 38 (8.8) | 15 (1–30) | 5 (7.1) | 11 (9.2) | 12 (8.6) | 10 (9.7) |
| Ceftriaxone IV + penicillin V PO | 3 (0.7) | 14 (9–21) | 1 (0.8) | 2 (1.4) | ||
| Penicillin G IV + doxycycline | 12 (2.8) | 21 (14–44) | 1 (1.4) | 3 (2.5) | 8 (5.8) | |
| Penicillin G IV + penicillin V PO | 3 (0.7) | 14 (14) | 1 (0.8) | 2 (1.4) | ||
| Penicillin G IV + ceftriaxone IV + doxycycline | 15 (3.5) | 21 (20–73) | 1 (1.4) | 9 (7.6) | 3 (2.2) | 2 (1.9) |
| No antibiotics | 13 (3.0) | … | 1 (1.4) | 3 (2.5) | 7 (5.0) | 2 (1.9) |
| Total No. of patients | 431 | … | 70 | 119 | 139 | 103 |
Data are presented as No. (%) unless otherwise indicated.
Abbreviations: IV, intravenous; PO, oral.
Antibiotic Treatment Type and Treatment Length Among 431 Patients With Lyme Neuroborreliosis
| Treatment . | No. (%) of Patients . | Mean Total Length of Treatment, d (Range) . | 1995–1999 . | 2000–2004 . | 2005–2009 . | 2010–2014 . |
|---|---|---|---|---|---|---|
| Penicillin G IV | 175 (40.6) | 10 (7–21) | 42 (60.0) | 66 (55.5) | 62 (44.6) | 5 (4.9) |
| Penicillin V PO | 1 (0.2) | 10 | 1 (1.4) | |||
| Doxycycline PO | 47 (10.9) | 21 (10–31) | 1 (1.4) | 10 (8.4) | 11 (7.9) | 25 (24.3) |
| Ceftriaxone IV | 85 (19.7) | 14 (10–24) | 15 (21.4) | 15 (12.6) | 24 (17.3) | 31 (30.1) |
| Ceftriaxone IV + doxycycline PO | 39 (9.0) | 21 (14–42) | 3 (4.3) | 8 (5.8) | 28 (27.2) | |
| Penicillin G IV + ceftriaxone IV | 38 (8.8) | 15 (1–30) | 5 (7.1) | 11 (9.2) | 12 (8.6) | 10 (9.7) |
| Ceftriaxone IV + penicillin V PO | 3 (0.7) | 14 (9–21) | 1 (0.8) | 2 (1.4) | ||
| Penicillin G IV + doxycycline | 12 (2.8) | 21 (14–44) | 1 (1.4) | 3 (2.5) | 8 (5.8) | |
| Penicillin G IV + penicillin V PO | 3 (0.7) | 14 (14) | 1 (0.8) | 2 (1.4) | ||
| Penicillin G IV + ceftriaxone IV + doxycycline | 15 (3.5) | 21 (20–73) | 1 (1.4) | 9 (7.6) | 3 (2.2) | 2 (1.9) |
| No antibiotics | 13 (3.0) | … | 1 (1.4) | 3 (2.5) | 7 (5.0) | 2 (1.9) |
| Total No. of patients | 431 | … | 70 | 119 | 139 | 103 |
| Treatment . | No. (%) of Patients . | Mean Total Length of Treatment, d (Range) . | 1995–1999 . | 2000–2004 . | 2005–2009 . | 2010–2014 . |
|---|---|---|---|---|---|---|
| Penicillin G IV | 175 (40.6) | 10 (7–21) | 42 (60.0) | 66 (55.5) | 62 (44.6) | 5 (4.9) |
| Penicillin V PO | 1 (0.2) | 10 | 1 (1.4) | |||
| Doxycycline PO | 47 (10.9) | 21 (10–31) | 1 (1.4) | 10 (8.4) | 11 (7.9) | 25 (24.3) |
| Ceftriaxone IV | 85 (19.7) | 14 (10–24) | 15 (21.4) | 15 (12.6) | 24 (17.3) | 31 (30.1) |
| Ceftriaxone IV + doxycycline PO | 39 (9.0) | 21 (14–42) | 3 (4.3) | 8 (5.8) | 28 (27.2) | |
| Penicillin G IV + ceftriaxone IV | 38 (8.8) | 15 (1–30) | 5 (7.1) | 11 (9.2) | 12 (8.6) | 10 (9.7) |
| Ceftriaxone IV + penicillin V PO | 3 (0.7) | 14 (9–21) | 1 (0.8) | 2 (1.4) | ||
| Penicillin G IV + doxycycline | 12 (2.8) | 21 (14–44) | 1 (1.4) | 3 (2.5) | 8 (5.8) | |
| Penicillin G IV + penicillin V PO | 3 (0.7) | 14 (14) | 1 (0.8) | 2 (1.4) | ||
| Penicillin G IV + ceftriaxone IV + doxycycline | 15 (3.5) | 21 (20–73) | 1 (1.4) | 9 (7.6) | 3 (2.2) | 2 (1.9) |
| No antibiotics | 13 (3.0) | … | 1 (1.4) | 3 (2.5) | 7 (5.0) | 2 (1.9) |
| Total No. of patients | 431 | … | 70 | 119 | 139 | 103 |
Data are presented as No. (%) unless otherwise indicated.
Abbreviations: IV, intravenous; PO, oral.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
